TRENTIN, Leonardo
 Distribuzione geografica
Continente #
EU - Europa 217
NA - Nord America 126
AS - Asia 44
Totale 387
Nazione #
US - Stati Uniti d'America 123
IE - Irlanda 105
SE - Svezia 51
DE - Germania 30
HK - Hong Kong 22
SG - Singapore 16
IT - Italia 12
CZ - Repubblica Ceca 8
UA - Ucraina 5
IN - India 4
CA - Canada 3
CN - Cina 2
FI - Finlandia 2
FR - Francia 2
GB - Regno Unito 2
Totale 387
Città #
Dublin 105
Hong Kong 22
Bremen 13
Chandler 13
Lawrence 13
Princeton 13
Boardman 11
Jacksonville 10
Brno 8
Singapore 8
Munich 5
Dearborn 4
Somaglia 4
Piemonte 3
Beijing 2
Gunzenhausen 2
Helsinki 2
Ottawa 2
San Mateo 2
Santa Clara 2
Wilmington 2
Arona 1
Cagliari 1
Frankfurt am Main 1
Grafing 1
Naples 1
Norwalk 1
Palermo 1
Sacramento 1
Toronto 1
Vergiate 1
Totale 256
Nome #
Genetic Landscape of Ultra-Stable Chronic Lymphocytic Leukemia Patients 53
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study 39
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 34
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab 32
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 32
Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group 30
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials 27
Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs 27
Prognostic impact and risk factors of infections in patients with chronic lymphocytic leukemia treated with ibrutinib 27
Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study 26
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases 25
Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model 25
IRF4 L116R mutation promotes proliferation of chronic lymphocytic leukemia B cells inducing MYC 24
Totale 401
Categoria #
all - tutte 3.754
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.754


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202010 0 0 0 0 0 1 4 0 2 2 1 0
2020/202117 1 0 1 0 3 2 3 0 3 1 3 0
2021/202247 0 0 2 1 2 0 1 0 3 1 11 26
2022/2023211 13 12 19 0 14 15 1 20 104 1 5 7
2023/202479 5 8 5 2 12 0 22 0 0 0 3 22
2024/202529 9 0 10 1 8 1 0 0 0 0 0 0
Totale 401